Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Lexeo Therapeutics, Inc. (LXEO)

Lexeo Therapeutics Q2 2026 net loss $25.9 million, or $0.30 per share, vs $0.60 a year earlier

Neutral Impact 3 of 5 earnings Written later

Lexeo Therapeutics reported second quarter 2026 results, with a net loss of $25.9 million, nearly flat from $26.1 million a year earlier, while the per-share loss fell to $0.30 from $0.60 on a larger share count. The company said it began its SUNRISE-FA 2 pivotal trial for LX2006 in June 2026 and had $234.2 million in cash, cash equivalents and investments, which it expects to fund operations into 2028.

Key points

  • Q2 2026 net loss was $25.9 million, or $0.30 per share, versus $26.1 million, or $0.60 per share, in Q2 2025; weighted average shares rose to 85,626,751 from 43,573,628.
  • Research and development expenses rose to $19.0 million from $14.7 million, while general and administrative expenses fell to $9.0 million from $16.0 million.
  • Cash, cash equivalents and investments were $234.2 million at June 30, 2026, down from $246.6 million at December 31, 2025.
  • The FDA granted RMAT designation for LX2020 in August 2026; topline data for LX2006 are expected in the second half of 2027.

The filing

CompanyLexeo Therapeutics, Inc. (LXEO)
Form8-K, current report
Filed with the SECAug 12, 2026, 7:02 AM ET
Accession number0001193125-26-345722

Items reported: 2.02 Results of Operations8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:45 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 12, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.